What are metabolic diseases of the heart?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Metabolic diseases of the heart are conditions where abnormal chemical processes affect cardiac function and structure, and their management should prioritize treating the underlying metabolic disorder with specific medications and lifestyle modifications to reduce morbidity, mortality, and improve quality of life. These conditions include diabetic cardiomyopathy, where high blood sugar damages heart muscle; cardiac amyloidosis, characterized by protein deposits in heart tissue; and disorders of fatty acid metabolism like carnitine deficiency, which impairs energy production in cardiac cells 1. Other examples include glycogen storage diseases affecting the heart, mitochondrial cardiomyopathies, and thyroid-related heart conditions.

Some key points to consider in the management of metabolic heart diseases include:

  • Treating the underlying metabolic disorder with specific medications, such as metformin or insulin for diabetes, and hormone replacement therapy for thyroid disorders
  • Implementing lifestyle modifications, such as dietary changes, including carbohydrate restriction in certain metabolic conditions, and increased physical activity
  • Regular cardiac monitoring to detect potential complications, such as heart failure, arrhythmias, or structural changes
  • Early diagnosis and intervention to prevent progression of the disease and reduce the risk of cardiovascular events

According to the most recent guidelines, the primary goal of treating metabolic syndrome is to reduce cardiovascular disease, and lifestyle modifications, such as weight loss and increased physical activity, should be the first-line therapy 1. Additionally, the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide 1 receptor agonists (GLP-1 RAs) has been shown to have a major benefit in reducing cardiovascular and kidney outcomes in people with type 2 diabetes 1.

Overall, the management of metabolic heart diseases requires a comprehensive approach that addresses the underlying metabolic disorder, as well as lifestyle modifications and regular cardiac monitoring to reduce morbidity, mortality, and improve quality of life.

From the Research

Metabolic Diseases of the Heart

Metabolic diseases of the heart encompass a heterogeneous group of conditions that commonly affect the heart and contribute adversely to cardiovascular outcomes. The heart, being a metabolically active organ, is often affected by inborn errors in metabolism (IEMs), presenting with cardiac manifestations such as:

  • Cardiomyopathy
  • Arrhythmia
  • Valvular dysfunction

Types of Metabolic Diseases

More than 40 IEMs are reported to cause cardiomyopathy, including:

  • Fatty acid oxidation defects
  • Glycogen storage diseases
  • Lysosomal storage diseases
  • Peroxisome storage diseases
  • Mitochondrial cardiomyopathies
  • Organic acidaemias
  • Aminoacidopathies
  • Congenital disorders of glycosylation 2

Effects on the Cardiovascular System

Many metabolic diseases result in pathological changes within the cardiovascular system, often with the most severe effects on the function of the heart and great vessels. Metabolic disorders affecting the heart include:

  • Disorders of amino acid metabolism
  • Storage diseases
  • Neuromuscular diseases
  • Diseases of metal and pigment metabolism
  • Carnitine deficiency
  • Connective tissue disorders 3

Metabolic Syndrome

The metabolic syndrome is a complex constellation of disorders, each one a significant risk factor for the development of cardiovascular disease (CVD). The individual components of the metabolic syndrome appear to be linked by the presence of insulin resistance 4. The clustering of metabolic and pathophysiological cardiovascular risk factors has long been recognized, and people with the metabolic syndrome have 50-60% higher cardiovascular risk than those without 5.

Cardiovascular Consequences

The metabolic syndrome is defined as the concurrence of obesity-associated cardiovascular risk factors, including abdominal obesity, impaired glucose tolerance, hypertriglyceridemia, decreased HDL cholesterol, and/or hypertension. Each component of the metabolic syndrome is an independent risk factor for cardiovascular disease, and the combination of these risk factors elevates rates and severity of cardiovascular disease 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The effects of metabolic diseases on the cardiovascular system.

The American journal of cardiovascular pathology, 1987

Research

Metabolic syndrome and cardiovascular disease.

Annals of clinical biochemistry, 2007

Research

Cardiovascular consequences of metabolic syndrome.

Translational research : the journal of laboratory and clinical medicine, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.